Lynthera is a biomedical company specializing in the research and development of drug delivery and formulation technology. We have created a novel technology platform for the controlled release of ocular therapeutics. This technology has been demonstrated through our development of a drug delivery contact lens (DDCL) product for the treatment of glaucoma, dry eye, and myopia control. With research support from NIH and NSF leading to positive pre-clinical results, the DDCL is planned for study in a clinical trial of glaucoma patients, followed by future clinical development of dry eye and other indications.